After hosting a call featuring a key opinion leader who treats a "significant number" of patients with moderate-to-severely active thyroid eye disease, Piper Jaffray analyst David Amsellem says he continues to view teprotumumab as a "potentially transformational opportunity" for Horizon Pharma. The commentary on the call "clearly underscores the extent to which systemic corticosteroids are inadequate for these patients," Amsellem tells investors in a research note. He believes experts views teprotumumab as "potentially paradigm-shifting" and reiterates an Overweight rating on Horizon Pharma with a $33 price target.